It has been about a month since the last earnings report for Elevance Health (ELV) . Shares have added about 7.3% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Elevance Health due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Elevance Health's Q2 Earnings Beat on L ...

FCF on the other hand stands at a meager $516 million for the TTM. However, as I always highlight when performing analysis on these kinds of beath insurance stocks: FCF is very volatile for these companies, so we have to gauge what I call a "normalized" FCF. "Normalized" FCF is the anoount of FCF ELV should be able to generate in an average year. In my last article, I calculated that ELV was able to convert 85% of EBIT into FCF (on average) for the fiscal years 2016-2022. I wil just use this conversion rati ...

Loading... Wednesday, Elevance Health Inc. ELV reported second-quarter revenues of $43.2 billion, down 0.4% yearover-year, marginally above the consensus of $43.05 billion. BofA Securities observes that Elevance Health has traditionally been seen as an investment lacking Medicare Advantage (MA) exposure. However, this perception may change following UnitedHealth's stronger-thanexpected results and a potentially improving regulatory landscape. The analyst writes, "Ultimately, we believe rates will reflect ac ...

RichVintage Elevance Health, Inc. (NYSE:ELV) has been a remarkable dividend grower in the past decade. ELV's balance sheet remains A-rated. ELV could be positioned to generate 30%+ cumulative total returns through 2026. | --- | --- | --- | --- | --- | --- | --- | --- | |----------------------------|-----------------------------------------------------|--------|---------------------------|---------|--------|---------------------|---------| | | Elevance Health Isted Statements (Unaudited) \n2024 | | Three Mon ...

The unrecognized loss for all expired and terminated cash flow hedges included in accumulated other comprehensive loss, net of tax, was $205 and $211 at June 30, 2024 and December 31, 2023, respectively. 7. Fair Value A summary of fair value measurements by level for assets and liabilities measured at fair value on a recurring basis at June 30, 2024 and December 31, 2023 is as follows: -19- In addition to the preceding disclosures on assets recorded at fair value in the consolidated balance sheets, FASB gui ...

Elevance Health, Inc. (ELV) reported second-quarter 2024 adjusted earnings of $10.12 per share, which outpaced the Zacks Consensus Estimate by 1.3%. The bottom line improved 12% year over year. The quarterly results were driven by improved product revenues in the CarelonRx business and a significant rise in net investment income. However, the upside was partly offset by a decline in Medicaid and Medicare membership and reduced premium revenues, thus impacting overall margins. Medical membership of Elevance ...

With that, I'd like to turn the call over to our CFO, Mark Kaye, to discuss our financial results and outlook in greater detail. Mark? Mark Kaye Thank you, Gail, and good morning to everyone on the line. As Gail shared, we reported second quarter results, including GAAP diluted earnings per share of $9.85 and adjusted diluted earnings per share of $10.12, representing growth of 12% year-over-year. We ended the second quarter with 45.8 million members, principally reflecting attrition in our Medicaid members ...

The Indianapolis company posted adjusted earnings per share (EPS) of $10.12 on operating revenue of $43.2 billion, topping analysts' consensus estimates compiled by Visible Alpha of $10 per share on revenue of $42.9 billion. Key Takeaways Elevance Health posted adjusted earnings per share (EPS) of $10.12 on revenue of $43.2 billion, beating analysts' expectations. Operating revenue fell year-over-year due to "attrition in Medicaid membership." The company reiterated its full-year adjusted EPS guidance of at ...

For the quarter ended June 2024, Elevance Health (ELV) reported revenue of $43.22 billion, down 0.4% over the same period last year. EPS came in at $10.12, compared to $9.04 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $42.99 billion, representing a surprise of +0.54%. The company delivered an EPS surprise of +1.30%, with the consensus EPS estimate being $9.99. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and ...

Loading... The decrease was driven by attrition in Medicaid membership, partially offset by higher premium yields reflecting the medical cost trend and growth in CarelonRx product revenue related to members served. Premiums fell 3.2% to $35.42 billion, and product revenue rose 14% to $5.53 billion. Services fees increased 18% to $2.28 billion. Reuters notes that Unlike rivals UnitedHealth Group Inc UNH and Humana Inc HUM, Elevance is less exposed to government-backed Medicare Advantage plans for people aged ...